The German coalition government will increase the fixed manufacturer rebate for pharmaceuticals instead of implementing a variable annual calculation. The rebate for patent-protected drugs will rise from 7% to 15.5%. The move aims to provide planning security for the industry while meeting health insurance savings targets.